LAVAL, QC, Sept. 9 /CNW/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today
announced that three separate posters will be presented at three upcoming
internationally prestigious medical meetings showcasing data on its novel
Two posters will be presented in mid-September, including:
The poster entitled: Modeling and Simulation to Optimize Efficacy and
Tolerability for a Once-a-day Trazodone Formulation at the 22nd European
College of Neuropsychopharmacology Congress to be held from September 12 to
16, 2009 in Istanbul, Turkey; and,
The poster entitled: Once-daily Trazodone: Overview of Pharmacokinetic
Properties, which will be presented at the 2009 American College of Clinical
Pharmacology (ACCP) 38th Annual Meeting in San Antonio, Texas from September
In October, during the 61st Institute on Psychiatric Services meeting to
be held from October 8 to 11th, 2009 in New York City the poster entitled: A
Novel Contramid(R)-based Reformulation of Trazodone in Major Depressive
Disorder: Characteristics of Antidepressant Response will be presented.
Complete copies of the three poster presentations will be available on
Labopharm's website (www.labopharm.com) at the conclusion of each scientific
About Labopharm's Novel Trazodone Formulation
Major depressive disorder (MDD) is a common mental illness often
characterized by a combination of symptoms that interfere with a person's
ability to work, sleep, study, eat, and enjoy once-pleasurable activities.
Treating MDD with antidepressants is challenging for physicians because
patient response to antidepressant drug therapy varies significantly. Research
has shown that as many as 28 percent of patients being treated with
antidepressants stop taking their medication within the first four weeks of
treatment and as many as 44 percent stop within the first 12 weeks. Frequently
cited reasons for discontinuing therapy include suboptimal efficacy on
depression symptoms, exacerbation of sleep disturbance, increased agitation,
slow onset of action, sexual dysfunction and weight gain.
Trazodone is a serotonin antagonist reuptake inhibitor with proven
efficacy as an antidepressant. Labopharm's novel formulation of trazodone is
designed to optimize the efficacy of trazodone, and address the major
challenges in treating depression.
Labopharm's trazodone formulation is currently under regulatory review by
the Food and Drug Administration (FDA) in the United States with an action
date under the Prescription Drug Users Fee Act (PDUFA) of February 11, 2010.
In Canada, the Company has filed a new drug submission for the trazodone
formulation with the Therapeutic Products Directorate (TPD) of Health Canada.
About Labopharm Inc.
Labopharm is an emerging leader in optimizing the performance of existing
small molecule drugs using its proprietary controlled-release technologies.
The Company's lead product, a unique once-daily formulation of tramadol, is
now available in 17 countries around the world, including the U.S., Canada,
major European markets and Australia. The Company's second product, a novel
formulation of trazodone for the treatment of major depressive disorder, is
under regulatory review in the U.S. by the FDA. The Company also has a robust
pipeline of follow-on products in both pre-clinical and clinical development.
Labopharm's vision is to become an integrated, international, specialty
pharmaceutical company with the capability to internally develop and
commercialize its own products. For more information, please visit
This press release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of factors,
including the uncertainties related to the regulatory process in various
countries for the approval of the Company's products and the successful
commercialization of the products throughout the world if they are approved.
Investors should consult the Company's ongoing quarterly filings and annual
reports for additional information on risks and uncertainties relating to
these forward-looking statements. The reader is cautioned not to rely on these
forward-looking statements. The Company disclaims any obligation to update
these forward-looking statements.
For further information:
For further information: At Labopharm: Mark D'Souza, Senior
Vice-President and Chief Financial Officer, Tel: (450) 686-0207; At The
Equicom Group: Jason Hogan, Media and Investor Relations, Tel: (416) 815-0700,
email@example.com; French: Joe Racanelli, Tel: (514) 844-7997,